91ÖĆƬł§

Published on Market Research Reports® Inc. ()

Home > Global Recombinant Activated Coagulation Factor VII Market Growth 2025-2031

Global Recombinant Activated Coagulation Factor VII Market Growth 2025-2031

Publication ID: 
LPI03257398
Publication Date: 
March 4, 2025
Pages: 
84
Publisher: 
LPI
Countries: 
Global [1]
USD 3,660.00

Please choose the suitable license type from above. More details are given under tab "Report License Types" below.

Pharmaceutical Manufacturing [2]
Healthcare [3]
Pharma & Healthcare [4]
Description: 

The global Recombinant Activated Coagulation Factor VII market size is predicted to grow from US$ 1285 million in 2025 to US$ 1610 million in 2031; it is expected to grow at a CAGR of 3.8% from 2025 to 2031.
Coagulation Factor VIIa, recombinant is a coagulation factor indicated for: Treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
The “Recombinant Activated Coagulation Factor VII Industry Forecast” looks at past sales and reviews total world Recombinant Activated Coagulation Factor VII sales in 2024, providing a comprehensive analysis by region and market sector of projected Recombinant Activated Coagulation Factor VII sales for 2025 through 2031. With Recombinant Activated Coagulation Factor VII sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Activated Coagulation Factor VII industry.
This Insight Report provides a comprehensive analysis of the global Recombinant Activated Coagulation Factor VII landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Activated Coagulation Factor VII portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Recombinant Activated Coagulation Factor VII market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Activated Coagulation Factor VII and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Activated Coagulation Factor VII.
This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Activated Coagulation Factor VII market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Vial
Prefilled Syringe
Segmentation by Application:
Hemophilia A
Hemophilia B
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Novo Nordisk
LFB SA HEMA Biologics
AryoGen Pharmed
Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant Activated Coagulation Factor VII market?
What factors are driving Recombinant Activated Coagulation Factor VII market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Activated Coagulation Factor VII market opportunities vary by end market size?
How does Recombinant Activated Coagulation Factor VII break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents: 

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Recombinant Activated Coagulation Factor VII Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Recombinant Activated Coagulation Factor VII by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Recombinant Activated Coagulation Factor VII by Country/Region, 2020, 2024 & 2031
2.2 Recombinant Activated Coagulation Factor VII Segment by Type
2.2.1 Vial
2.2.2 Prefilled Syringe
2.3 Recombinant Activated Coagulation Factor VII Sales by Type
2.3.1 Global Recombinant Activated Coagulation Factor VII Sales Market Share by Type (2020-2025)
2.3.2 Global Recombinant Activated Coagulation Factor VII Revenue and Market Share by Type (2020-2025)
2.3.3 Global Recombinant Activated Coagulation Factor VII Sale Price by Type (2020-2025)
2.4 Recombinant Activated Coagulation Factor VII Segment by Application
2.4.1 Hemophilia A
2.4.2 Hemophilia B
2.4.3 Other
2.5 Recombinant Activated Coagulation Factor VII Sales by Application
2.5.1 Global Recombinant Activated Coagulation Factor VII Sale Market Share by Application (2020-2025)
2.5.2 Global Recombinant Activated Coagulation Factor VII Revenue and Market Share by Application (2020-2025)
2.5.3 Global Recombinant Activated Coagulation Factor VII Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Recombinant Activated Coagulation Factor VII Breakdown Data by Company
3.1.1 Global Recombinant Activated Coagulation Factor VII Annual Sales by Company (2020-2025)
3.1.2 Global Recombinant Activated Coagulation Factor VII Sales Market Share by Company (2020-2025)
3.2 Global Recombinant Activated Coagulation Factor VII Annual Revenue by Company (2020-2025)
3.2.1 Global Recombinant Activated Coagulation Factor VII Revenue by Company (2020-2025)
3.2.2 Global Recombinant Activated Coagulation Factor VII Revenue Market Share by Company (2020-2025)
3.3 Global Recombinant Activated Coagulation Factor VII Sale Price by Company
3.4 Key Manufacturers Recombinant Activated Coagulation Factor VII Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Activated Coagulation Factor VII Product Location Distribution
3.4.2 Players Recombinant Activated Coagulation Factor VII Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Recombinant Activated Coagulation Factor VII by Geographic Region
4.1 World Historic Recombinant Activated Coagulation Factor VII Market Size by Geographic Region (2020-2025)
4.1.1 Global Recombinant Activated Coagulation Factor VII Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Recombinant Activated Coagulation Factor VII Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Recombinant Activated Coagulation Factor VII Market Size by Country/Region (2020-2025)
4.2.1 Global Recombinant Activated Coagulation Factor VII Annual Sales by Country/Region (2020-2025)
4.2.2 Global Recombinant Activated Coagulation Factor VII Annual Revenue by Country/Region (2020-2025)
4.3 Americas Recombinant Activated Coagulation Factor VII Sales Growth
4.4 APAC Recombinant Activated Coagulation Factor VII Sales Growth
4.5 Europe Recombinant Activated Coagulation Factor VII Sales Growth
4.6 Middle East & Africa Recombinant Activated Coagulation Factor VII Sales Growth
5 Americas
5.1 Americas Recombinant Activated Coagulation Factor VII Sales by Country
5.1.1 Americas Recombinant Activated Coagulation Factor VII Sales by Country (2020-2025)
5.1.2 Americas Recombinant Activated Coagulation Factor VII Revenue by Country (2020-2025)
5.2 Americas Recombinant Activated Coagulation Factor VII Sales by Type (2020-2025)
5.3 Americas Recombinant Activated Coagulation Factor VII Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Activated Coagulation Factor VII Sales by Region
6.1.1 APAC Recombinant Activated Coagulation Factor VII Sales by Region (2020-2025)
6.1.2 APAC Recombinant Activated Coagulation Factor VII Revenue by Region (2020-2025)
6.2 APAC Recombinant Activated Coagulation Factor VII Sales by Type (2020-2025)
6.3 APAC Recombinant Activated Coagulation Factor VII Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Recombinant Activated Coagulation Factor VII by Country
7.1.1 Europe Recombinant Activated Coagulation Factor VII Sales by Country (2020-2025)
7.1.2 Europe Recombinant Activated Coagulation Factor VII Revenue by Country (2020-2025)
7.2 Europe Recombinant Activated Coagulation Factor VII Sales by Type (2020-2025)
7.3 Europe Recombinant Activated Coagulation Factor VII Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Recombinant Activated Coagulation Factor VII by Country
8.1.1 Middle East & Africa Recombinant Activated Coagulation Factor VII Sales by Country (2020-2025)
8.1.2 Middle East & Africa Recombinant Activated Coagulation Factor VII Revenue by Country (2020-2025)
8.2 Middle East & Africa Recombinant Activated Coagulation Factor VII Sales by Type (2020-2025)
8.3 Middle East & Africa Recombinant Activated Coagulation Factor VII Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Activated Coagulation Factor VII
10.3 Manufacturing Process Analysis of Recombinant Activated Coagulation Factor VII
10.4 Industry Chain Structure of Recombinant Activated Coagulation Factor VII
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Activated Coagulation Factor VII Distributors
11.3 Recombinant Activated Coagulation Factor VII Customer
12 World Forecast Review for Recombinant Activated Coagulation Factor VII by Geographic Region
12.1 Global Recombinant Activated Coagulation Factor VII Market Size Forecast by Region
12.1.1 Global Recombinant Activated Coagulation Factor VII Forecast by Region (2026-2031)
12.1.2 Global Recombinant Activated Coagulation Factor VII Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Recombinant Activated Coagulation Factor VII Forecast by Type (2026-2031)
12.7 Global Recombinant Activated Coagulation Factor VII Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Novo Nordisk
13.1.1 Novo Nordisk Company Information
13.1.2 Novo Nordisk Recombinant Activated Coagulation Factor VII Product Portfolios and Specifications
13.1.3 Novo Nordisk Recombinant Activated Coagulation Factor VII Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Novo Nordisk Main Business Overview
13.1.5 Novo Nordisk Latest Developments
13.2 LFB SA HEMA Biologics
13.2.1 LFB SA HEMA Biologics Company Information
13.2.2 LFB SA HEMA Biologics Recombinant Activated Coagulation Factor VII Product Portfolios and Specifications
13.2.3 LFB SA HEMA Biologics Recombinant Activated Coagulation Factor VII Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 LFB SA HEMA Biologics Main Business Overview
13.2.5 LFB SA HEMA Biologics Latest Developments
13.3 AryoGen Pharmed
13.3.1 AryoGen Pharmed Company Information
13.3.2 AryoGen Pharmed Recombinant Activated Coagulation Factor VII Product Portfolios and Specifications
13.3.3 AryoGen Pharmed Recombinant Activated Coagulation Factor VII Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 AryoGen Pharmed Main Business Overview
13.3.5 AryoGen Pharmed Latest Developments
14 Research Findings and Conclusion

License Types: 

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

Ěý

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

Ěý

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL:/lpi/global-recombinant-activated-coagulation-factor-vii-market-growth-2025-2031

Links
[1] /countries/global[2] /pharmaceutical-manufacturing[3] /healthcare[4] /pharma-healthcare